Snapshot from Aug 16, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Cytokinetics gets UK approval for aficamten
Regulatory regulatory approval

Cytokinetics gets UK approval for aficamten

Analysis based on 7 articles · First reported Jul 30, 2026 · Last updated Jul 30, 2026

Sentiment
40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The regulatory approvals in the UK open a new revenue stream for Cytokinetics in a major market, likely boosting investor confidence. The positive NICE guidance ensures NHS coverage, which could drive adoption and sales of aficamten.

Biotechnology Pharmaceuticals
Event Summary

Cytokinetics announced that the UK United Kingdom — Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. Concurrently, the United Kingdom — National Institute for Health and Care Research (NICE) issued positive guidance recommending aficamten for use in Bret Engemann and United Kingdom — Wales. The approval is based on the phase 3 SEQUOIA-HCM trial showing statistically significant improvement in peak oxygen uptake. Cytokinetics expects to make the drug available through the NHS later in 2026.

Key Actions
100 United Kingdom — Medicines and Healthcare products Regulatory Agency granted marketing authorisation Cytokinetics
90 United Kingdom — National Institute for Health and Care Research issued positive guidance Cytokinetics
Entities Involved
stock
Cytokinetics
Cytokinetics received marketing authorisation and positive NICE guidance for its drug aficamten in the UK, enabling commercial launch and potential revenue growth.
Importance 100.0 Sentiment 60.0
govactor
United Kingdom — Medicines and Healthcare products Regulatory Agency
MHRA granted marketing authorisation for aficamten, fulfilling its regulatory role.
Importance 80.0 Sentiment 0.0
govactor
United Kingdom — National Institute for Health and Care Research
NICE issued positive guidance recommending aficamten for use in Bret Engemann and United Kingdom — Wales, enabling NHS coverage.
Importance 80.0 Sentiment 0.0
cnt
United Kingdom
The UK is the jurisdiction where aficamten received approval, expanding treatment options for oHCM patients.
Importance 50.0 Sentiment 0.0
govactor
United Kingdom — National Health Service
NHS will provide aficamten to eligible patients following the NICE recommendation, expected later in 2026.
Importance 50.0 Sentiment 0.0
per
Bret Engemann
Bret Engemann is one of the regions where NICE guidance applies, allowing patient access via NHS.
Importance 40.0 Sentiment 0.0
loc
United Kingdom — Wales
United Kingdom — Wales is one of the regions where NICE guidance applies, allowing patient access via NHS.
Importance 40.0 Sentiment 0.0
per
David Joseph
David Joseph, Senior Vice President and Head of Europe at Cytokinetics, commented on the approvals.
Importance 30.0 Sentiment 0.0
per
Diane Weiser
Diane Weiser is the Senior Vice President of Corporate Affairs at Cytokinetics, listed as a contact.
Importance 10.0 Sentiment 0.0
Relationships
United Kingdom — Medicines and Healthcare products Regulatory Agency related ↔ United Kingdom
United Kingdom — National Institute for Health and Care Research related ↔ United Kingdom
United Kingdom — National Institute for Health and Care Research related ↔ United Kingdom — National Health Service
United Kingdom related ↔ United Kingdom — National Health Service
United Kingdom related ↔ Bret Engemann
United Kingdom — National Health Service related ↔ Bret Engemann
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.